PHARMA SHOULD ENCOURAGE THE INTEREST OF PHYSICIANS TO PARTICIPATE IN CLINICAL TRIALS
India is globally recognized as an attractive destination for conducting clinical trials owing to its huge patient pool, a technically competent workforce and significant cost savings. However, it accounts for less than 1.4% of global clinical trials at present. While the government is already working on the regulatory environment to increase these numbers, it will be equally important to encourage higher participation from the medical community.
Physician-researchers play a huge role in improving the quality of both services and research studies. In India, the linguistic barrier is a major problem for recruiting patients and giving them proper instructions and knowledge about trials. Hence, it is of utmost importance for physicians from all across the country to take part in clinical trials. Since a majority of trials are industry-sponsored, it is crucial for pharma to examine and eliminate factors that hold physicians back from being actively involved in regulatory studies.
Docplexus, a largest and fastest growing online community for doctors of India, conducted a survey on 1105 doctors specializing in Pharmacology/Clinical Pharmacology, General Medicine, Cardiology, Orthopedics, Neurology and Urology to understand their inclinations and concerns regarding clinical trials in India.
It revealed following key insights:
Doctors are interested in clinical trials data
Doctors want to be updated on clinical practices
Several barriers restrict physicians’ participation in clinical trials
Poor access to latest practices is creating misconceptions
It is evident that physicians acknowledge the huge role played by clinical trials in improving healthcare outcomes. Their participation will only increase as they get adequate financial assistance, protected time for research, help with data management and regular updates on regulations and practices.
KEY TAKEAWAYS FOR PHARMA
Doctors track clinical trials data to gauge the prevalence of disease, stay updated on new molecules, and understand the role of ethnicity in patient’s responsiveness to treatment.
Pharma should encourage the interest of physicians to participate in clinical trials by giving them adequate financial assistance.
There should be a system or information portal in place to educate and train the doctors about regulations and trials methodology in clinical trials.